> News
 > MaaT Pharma Receives U.S. FDA Response
News
03/02/2023

MaaT Pharma Receives U.S. FDA Response

Outlining Path Forward for Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease and Reports Cash and Revenues for Fourth Quarter 2022.

Access the press release

 

Our news

Events
19/01/2023
Microbiota & Health Day 2023
> READ
News
26/04/2023
MaaT Pharma Announces U.S. FDA Lifts Clinical Hold on Phase 3 Investigational New Drug Application for MaaT013 in Patients with Acute Graft-versus-Host Disease
> READ
News
16/01/2023
Everimmune launches Phase I clinical trial for its oncobiotic drug candidate in lung and kidney cancer
> READ
> See all news